Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia
Purpose: To compare the clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia (CAP). Patients and methods: We identified patients with severe CAP who received piperacillin-tazobactam based on a nine-center registry database. Further...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Journal of Infection and Public Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034122001861 |
| _version_ | 1817982299604516864 |
|---|---|
| author | Cheng-Yi Wang Chia-Hung Chen Chih-Yen Tu Wei-Chih Chen Li-Kuo Kuo Yao-Tung Wang Pin-Kuei Fu Shih-Chi Ku Wen-Feng Fang Chin-Ming Chen Chih-Cheng Lai |
| author_facet | Cheng-Yi Wang Chia-Hung Chen Chih-Yen Tu Wei-Chih Chen Li-Kuo Kuo Yao-Tung Wang Pin-Kuei Fu Shih-Chi Ku Wen-Feng Fang Chin-Ming Chen Chih-Cheng Lai |
| author_sort | Cheng-Yi Wang |
| collection | DOAJ |
| description | Purpose: To compare the clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia (CAP). Patients and methods: We identified patients with severe CAP who received piperacillin-tazobactam based on a nine-center registry database. Furthermore, we classified the patients in three hospitals, which used only branded piperacillin-tazobactam as the study group, and the patients in six other hospitals, which used both branded and generic products as the control group. Results: A total of 472 patients (n = 263 in the study group and n = 209 in the control group) with severe CAP were included. The study group using branded piperacillin-tazobactam had higher odds of clinical cure (adjusted odds ratio [OR] = 3.77, 95 % confidence interval [CI], 1.93–7.37) and lower odds of treatment failure (adjusted OR = 0.28, 95 % CI, 0.13–0.58) than the control group receiving either branded or generic piperacillin-tazobactam. In addition, the study group was associated with higher odds of clinical effectiveness (adjusted OR = 2.95, 95 % CI, 1.46–6.11), less odds of clinical ineffectiveness (adjusted OR = 0.39, 95 % CI, 0.18–0.81), and lower risk of in-hospital mortality (adjusted OR = 0.39, 95 % CI, 0.21–0.73). Conclusion: Based on the findings of the present study using indirect comparison, the clinical effectiveness of generic piperacillin-tazobactam for treating patients with severe CAP might not be as good as that of brand-name products. |
| first_indexed | 2024-04-13T23:19:01Z |
| format | Article |
| id | doaj.art-dc05d5ce7bf04d1db636f3f1660a086d |
| institution | Directory Open Access Journal |
| issn | 1876-0341 |
| language | English |
| last_indexed | 2024-04-13T23:19:01Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Infection and Public Health |
| spelling | doaj.art-dc05d5ce7bf04d1db636f3f1660a086d2022-12-22T02:25:20ZengElsevierJournal of Infection and Public Health1876-03412022-09-01159961965Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumoniaCheng-Yi Wang0Chia-Hung Chen1Chih-Yen Tu2Wei-Chih Chen3Li-Kuo Kuo4Yao-Tung Wang5Pin-Kuei Fu6Shih-Chi Ku7Wen-Feng Fang8Chin-Ming Chen9Chih-Cheng Lai10Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 231, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, TaiwanDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Pulmonary and Critical Care Medicine, MacKay Memorial Hospital, Taipei 10449, TaiwanDivision of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, TaiwanDepartment of Critical Care Medicine, Taichung Veterans General Hospital, Taichung 407219, TaiwanDivision of Chest Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, TaiwanDepartment of Intensive Care Medicine, Chi Mei Medical Centre, Tainan 710, TaiwanDivision of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan; Correspondence to: Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, TaiwanPurpose: To compare the clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia (CAP). Patients and methods: We identified patients with severe CAP who received piperacillin-tazobactam based on a nine-center registry database. Furthermore, we classified the patients in three hospitals, which used only branded piperacillin-tazobactam as the study group, and the patients in six other hospitals, which used both branded and generic products as the control group. Results: A total of 472 patients (n = 263 in the study group and n = 209 in the control group) with severe CAP were included. The study group using branded piperacillin-tazobactam had higher odds of clinical cure (adjusted odds ratio [OR] = 3.77, 95 % confidence interval [CI], 1.93–7.37) and lower odds of treatment failure (adjusted OR = 0.28, 95 % CI, 0.13–0.58) than the control group receiving either branded or generic piperacillin-tazobactam. In addition, the study group was associated with higher odds of clinical effectiveness (adjusted OR = 2.95, 95 % CI, 1.46–6.11), less odds of clinical ineffectiveness (adjusted OR = 0.39, 95 % CI, 0.18–0.81), and lower risk of in-hospital mortality (adjusted OR = 0.39, 95 % CI, 0.21–0.73). Conclusion: Based on the findings of the present study using indirect comparison, the clinical effectiveness of generic piperacillin-tazobactam for treating patients with severe CAP might not be as good as that of brand-name products.http://www.sciencedirect.com/science/article/pii/S1876034122001861Brand-nameCommunity-acquired pneumoniaEffectivenessGeneric namePiperacillin-tazobactam |
| spellingShingle | Cheng-Yi Wang Chia-Hung Chen Chih-Yen Tu Wei-Chih Chen Li-Kuo Kuo Yao-Tung Wang Pin-Kuei Fu Shih-Chi Ku Wen-Feng Fang Chin-Ming Chen Chih-Cheng Lai Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia Journal of Infection and Public Health Brand-name Community-acquired pneumonia Effectiveness Generic name Piperacillin-tazobactam |
| title | Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia |
| title_full | Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia |
| title_fullStr | Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia |
| title_full_unstemmed | Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia |
| title_short | Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia |
| title_sort | clinical effectiveness of branded versus generic piperacillin tazobactam for treating severe community acquired pneumonia |
| topic | Brand-name Community-acquired pneumonia Effectiveness Generic name Piperacillin-tazobactam |
| url | http://www.sciencedirect.com/science/article/pii/S1876034122001861 |
| work_keys_str_mv | AT chengyiwang clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT chiahungchen clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT chihyentu clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT weichihchen clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT likuokuo clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT yaotungwang clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT pinkueifu clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT shihchiku clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT wenfengfang clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT chinmingchen clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia AT chihchenglai clinicaleffectivenessofbrandedversusgenericpiperacillintazobactamfortreatingseverecommunityacquiredpneumonia |